97 related articles for article (PubMed ID: 16722624)
1. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
Vachal P; Hale JJ; Lu Z; Streckfuss EC; Mills SG; MacCoss M; Yin DH; Algayer K; Manser K; Kesisoglou F; Ghosh S; Alani LL
J Med Chem; 2006 Jun; 49(11):3060-3. PubMed ID: 16722624
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
Arns S; Gibe R; Moreau A; Monzur Morshed M; Young RN
Bioorg Med Chem; 2012 Mar; 20(6):2131-40. PubMed ID: 22341574
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in vivo bioactivity of lipophilic alendronate derivatives against osteoporosis.
Lu TL; Hu HJ; Zhao W; Chen T
Drug Dev Ind Pharm; 2011 Jun; 37(6):656-63. PubMed ID: 21449707
[TBL] [Abstract][Full Text] [Related]
4. Electrospray tandem mass spectrometry of alendronate analogues: fingerprints for characterization of new potential prodrugs.
Hardouin J; Guénin E; Malosse C; Caron M; Lecouvey M
Rapid Commun Mass Spectrom; 2008 Aug; 22(15):2287-300. PubMed ID: 18613280
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
Xie H; Chen G; Young RN
J Med Chem; 2017 Aug; 60(16):7012-7028. PubMed ID: 28699744
[TBL] [Abstract][Full Text] [Related]
6. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Kulkamp IC; Guterres SS; Pohlmann AR
Eur J Pharm Sci; 2010 Aug; 40(5):441-7. PubMed ID: 20471479
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of poorly absorptive drugs with mucoadhesive polymers for the improvement of oral absorption of drugs.
Sakuma S; Matsumoto T; Yamashita S; Wang Y; Lu ZR
J Control Release; 2007 Nov; 123(3):195-202. PubMed ID: 17888541
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Kusamori K; Katsumi H; Abe M; Ueda A; Sakai R; Hayashi R; Hirai Y; Quan YS; Kamiyama F; Sakane T; Yamamoto A
J Bone Miner Res; 2010 Dec; 25(12):2582-91. PubMed ID: 20533374
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
10. Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats.
Katsumi H; Nakatani M; Sano J; Abe M; Kusamori K; Kurihara M; Shiota R; Takashima M; Fujita T; Sakane T; Hibi T; Yamamoto A
Int J Pharm; 2010 Nov; 400(1-2):124-30. PubMed ID: 20816731
[TBL] [Abstract][Full Text] [Related]
11. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
12. Alendronate sodium.
Ananchenko G; Novakovic J; Tikhomirova A
Profiles Drug Subst Excip Relat Methodol; 2013; 38():1-33. PubMed ID: 23668401
[TBL] [Abstract][Full Text] [Related]
13. Influence of estrogen deficiency and its treatment with alendronate and estrogen on bone density around osseointegrated implants: radiographic study in female rats.
Giro G; Gonçalves D; Sakakura CE; Pereira RM; Marcantonio Júnior E; Orrico SR
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Feb; 105(2):162-7. PubMed ID: 18230387
[TBL] [Abstract][Full Text] [Related]
14. A peptide prodrug approach for improving bisphosphonate oral absorption.
Ezra A; Hoffman A; Breuer E; Alferiev IS; Mönkkönen J; El Hanany-Rozen N; Weiss G; Stepensky D; Gati I; Cohen H; Törmälehto S; Amidon GL; Golomb G
J Med Chem; 2000 Oct; 43(20):3641-52. PubMed ID: 11020278
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and alendronate therapies may prevent the influence of estrogen deficiency on the tooth-supporting alveolar bone: a histometric study in rats.
Duarte PM; Gonçalves P; Casati MZ; de Toledo S; Sallum EA; Nociti FH
J Periodontal Res; 2006 Dec; 41(6):541-6. PubMed ID: 17076779
[TBL] [Abstract][Full Text] [Related]
16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
18. Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model.
Thomopoulos S; Matsuzaki H; Zaegel M; Gelberman RH; Silva MJ
J Orthop Res; 2007 Apr; 25(4):473-9. PubMed ID: 17205555
[TBL] [Abstract][Full Text] [Related]
19. Microencapsulation of sodium alendronate reduces drug mucosal damage in rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Guterres SS; Pohlmann AR
Drug Deliv; 2010 May; 17(4):231-7. PubMed ID: 20196631
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Babb RR
N Engl J Med; 2008 Mar; 358(12):1302-3; author reply 1303-4. PubMed ID: 18357641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
